Marekani - Kiingereza - NLM (National Library of Medicine)

micro labs limited - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine  citrate is indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components. caffeine citrate oral solution each bottle (vial) of caffeine citrate oral solution contains a total of 60 mg of caffeine citrate in 3 ml (20 mg/ml). information and instructions for use this leaflet tells you about caffeine citrate oral solution (kaf-een sit-rate) and how to give it to your baby.  read the following information before giving this medicine to your baby.  completely discuss caffeine citrate oral solution with your baby’s doctor.  continue to discuss any questions you have about this medicine at your baby’s checkups. after you remove your baby’s dose, throw away the open bottle (vial) and all medicine left in it .  use each vial of caffeine citrate oral solution for only one dose.  there will be extra medicine left in the vial after one dose is remo

Marekani - Kiingereza - NLM (National Library of Medicine)

larken laboratories inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen 325 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are contraindicated for: - all children younger than 12 years of age [see warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and p

Marekani - Kiingereza - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital 50 mg - butalbital, aspirin, and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of butalbital, aspirin, and caffeine capsules in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. butalbital, aspirin, and caffeine capsules are contraindicated under the following conditions: - hypersensitivity or intolerance to aspirin, caffeine, or butalbital. - patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin k deficiency and severe liver damage). - patients with the syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin or other nonsteroidal anti-inflammatory drugs. anaphylactoid reactions have occurred in such patients. - peptic ul

Marekani - Kiingereza - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital 50 mg - butalbital, acetaminophen and caffeine tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: - hypersensitivity or intolerance to any component of this product. - patients with porphyria. butalbital: barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an

Marekani - Kiingereza - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital, acetaminophen, and caffeine tablets, usp are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: - hypersensitivity or intolerance to any component of this product - patients with porphyria. barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intox

Marekani - Kiingereza - NLM (National Library of Medicine)

atland pharmaceuticals, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate tablets for use in patients for whom alternative  treatment options [e.g., non-opioidanalgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine and dihydrocodeine bitartrate tablets are contraindicated for: all - children younger than 12 years of age [see  warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see  warnings and precau

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - caffeine; phenylephrine hydrochloride; paracetamol - oral capsule - 25mg ; 6.1mg ; 500mg

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

haleon new zealand ulc - caffeine 25mg;  ; paracetamol 500mg;  ;  ;  ; phenylephrine hydrochloride 5mg;  ;   - film coated tablet - active: caffeine 25mg   paracetamol 500mg       phenylephrine hydrochloride 5mg     excipient: hypromellose mastercote fa1202 macrogol 400 maize starch microcrystalline cellulose potassium sorbate povidone purified talc sodium laurilsulfate starch stearic acid sunset yellow fcf

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - paracetamol; caffeine; phenylephrine hydrochloride - capsule, hard - 300/25/5 milligram(s) - other cold preparations

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - paracetamol; caffeine - capsule, hard - 500mg/65 milligram(s) - anilides; paracetamol